<span item_type="fundamental" item_id="f3b81526052b86ef65172ae8b69f6872" counter_id="ST/US/DMAAR" env="prod"></span><span item_type="announcement" item_id="584246473839677441" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD 0.07.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -2.712 M.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not commenced any operations and does not expect to generate operating revenues until after the completion of its initial Business Combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025112096/ea0264976-10q_drugs.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>For the three months ended September 30, 2025, the company reported a net income of $2,184,563, primarily due to interest earned on cash and investments held in the trust account amounting to $2,448,266, offset by general and administrative costs of $263,703.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025112096/ea0264976-10q_drugs.htm"></span></li><li>For the nine months ended September 30, 2025, the company reported a net income of $5,727,685, with interest earned on cash and investments held in the trust account totaling $6,454,232, offset by general and administrative costs of $726,547.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025112096/ea0264976-10q_drugs.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the nine months ended September 30, 2025 was - $414,007.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025112096/ea0264976-10q_drugs.htm"></span></li><li>Net cash used in investing activities for the same period was - $231,150,000, primarily due to the investment of cash into the Trust Account.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025112096/ea0264976-10q_drugs.htm"></span></li><li>Net cash provided by financing activities was $231,563,373, which included proceeds from the sale of Units and Private Placement Units.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025112096/ea0264976-10q_drugs.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The company has placed $231,150,000 in a trust account from the net proceeds of the sale of Units in the Initial Public Offering and the sale of Private Placement Units.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025112096/ea0264976-10q_drugs.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li>The company intends to focus on companies in the pharmaceutical industry for its Business Combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025112096/ea0264976-10q_drugs.htm"></span></li><li>The company will have up to 15 months from the closing of the Initial Public Offering (April 29, 2026) to complete a Business Combination, with the possibility of extending this period up to 21 months.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025112096/ea0264976-10q_drugs.htm"></span></li><li>If unable to complete a Business Combination within the specified period, the company will redeem 100% of the issued and outstanding public shares and seek to liquidate and dissolve.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025112096/ea0264976-10q_drugs.htm"></span></li></ul>

DRUGS MADE IN AMER ACQUISITION CORP COM USD0.0001 15/10/2029 (SUB/RIGHTS) | 10-Q: FY2025 Q3 Revenue: USD 0